| Original language | English (US) |
|---|---|
| Pages (from-to) | 1692-1694 |
| Number of pages | 3 |
| Journal | Annals of Oncology |
| Volume | 28 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2017 |
ASJC Scopus subject areas
- Hematology
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of Oncology, Vol. 28, No. 8, 01.08.2017, p. 1692-1694.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Precision, complexity and stigma in advanced prostate cancer terminology
T2 - It is time to move away from 'castration-resistant' prostate cancer
AU - ANZUP Consumer Advisory Panel
AU - Pezaro, C. J.
AU - Omlin, A.
AU - Mastris, K.
AU - Attard, G.
AU - Beer, T. M.
AU - Chi, K. N.
AU - Chowdhury, S.
AU - Davis, I. D.
AU - Drake, C. G.
AU - de Bono, J. S.
AU - Efstathiou, E.
AU - Gravis, G.
AU - Higano, C. S.
AU - Hussain, M.
AU - James, N.
AU - Logothetis, C. J.
AU - Morgans, A.
AU - Parker, C.
AU - Ryan, C. J.
AU - Saad, F.
AU - Sartor, O.
AU - Small, E. J.
AU - Sternberg, C. N.
AU - Sweeney, C. J.
AU - Tannock, I.
AU - Tombal, B.
AU - Gillessen, S.
N1 - Funding Information: CP: advisory boards (compensated): Novartis. Honoraria: Janssen, Pfizer, Sanofi, Novartis, Astellas. Travel support: Pfizer, Sanofi, Amgen. AO: advisory boards (compensated, institutional): Bayer, Astellas, Janssen, Sanofi, Pfizer. Travel support: Bayer, Astellas, Janssen, Sanofi. Research support (institutional): Janssen, Teva. FS: advisory boards, honoraria and research: Amgen, Astellas. Bayer, Janssen, Sanofi, Takeda. SG: advisory boards: AAA, Astellas, Bayer, Curevac, Dendreon, Janssen Cilag, Janssen Diagnostics, Millennium, Novartis, Orion Pharma, Pfizer, Sanofi Aventis. Advisory Boards (uncompensated): ProteoMediX, ESSA Pharmaceuticals Corp. Speakers Bureau (without personal honorarium): Amgen, Astellas, Bayer, Janssen Cilag, Novartis, Sanofi Aventis. IDD is supported by an NHMRC Practitioner Fellowship (APP1102604).
PY - 2017/8/1
Y1 - 2017/8/1
UR - http://www.scopus.com/inward/record.url?scp=85029301441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029301441&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdx312
DO - 10.1093/annonc/mdx312
M3 - Editorial
C2 - 28838209
AN - SCOPUS:85029301441
SN - 0923-7534
VL - 28
SP - 1692
EP - 1694
JO - Annals of Oncology
JF - Annals of Oncology
IS - 8
ER -